Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 6c
November 12, 2019 4:36 PM ESTLineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $567 thousand versus the consensus estimate of $810 thousand.
New Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last VisitImplemented Significant Additional Cost-Cutting Measures to Reduce Budget for 2020Received CE Mark Approval for Renevia®; Working to Identify European Commercial PartnerConducted Sales of 6.25 Million Shares of OncoCyte Corporation for $10.7 Million in Net ProceedsStrengthened... More